This CPB is revised to state that bortezomib is considered medically necessary for antibody mediated rejection of kidney, liver and other solid organs. This CPB is revised to state that bortezomib is considered medically necessary for monomorphic epitheliotropic intestinal T-cell lymphoma when criteria are met. This CPB is revised to state that bortezomib for adult T-cell leukemia/lymphoma is considered medically necessary as second-line therapy as a single agent for nonresponders to first-line therapy for acute disease or lymphoma or as subsequent therapy after high dose therapy/autologous stem cell rescue (HDT/ASCR).